In vitro characterization of delafloxacin activity against intracellular Legionella: Exploring new treatment options for Legionnaires’ disease
Based on the results obtained, the higher intracellular activity of delafloxacin compared with levofloxacin and its better safety profile should be confirmed in phase IV clinical real-life cases of Legionnaires' disease.
Authors
- Nieves Sopena
- María Luisa Pedro-Botet (ORCID: https://orcid.org/0000-0001-7252-3191)
- Esteban Reynaga (ORCID: https://orcid.org/0000-0002-4069-6087)
- Sara Quero (ORCID: https://orcid.org/0000-0002-6454-6358)
- Noemí Párraga-Niño (ORCID: https://orcid.org/0000-0003-0376-5036)
- Elisenda Arqué (ORCID: https://orcid.org/0000-0002-7468-6979)
- Roger Cortès-Tarragó
- Javier Díez de los Ríos (ORCID: https://orcid.org/0000-0002-4011-5211)
- Lluc Vinyeta
- Maria Basart Altieri
- Sarahi Marieliza Elizondo
Institutions
- Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (ES)
- Hospital Universitari Germans Trias i Pujol (ES)
Publication Details
- Journal
- International Journal of Infectious Diseases
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1016/j.ijid.2025.108165
- Primary Topic
- Legionella and Acanthamoeba research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Centres de Recerca de Catalunya
- Generalitat de Catalunya
- Universitat Autònoma de Barcelona
- Instituto de Salud Carlos III